BioAtla Inc (NASDAQ: BCAB) is -19.11% lower on its value in year-to-date trading and has touched a low of $1.14 and a high of $4.02 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BCAB stock was last observed hovering at around $2.19 in the last trading session, with the day’s loss setting it -0.2%.
Currently trading at $1.99, the stock is -1.97% and 3.60% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing -9.13% at the moment leaves the stock -7.13% off its SMA200. BCAB registered 34.46% gain for a year compared to 6-month loss of -33.67%. The firm has a 50-day simple moving average (SMA 50) of $1.9167 and a 200-day simple moving average (SMA200) of $2.142825.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 2.05% gain in the last 1 month and extending the period to 3 months gives it a 5.85%, and is -3.40% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.22% over the week and 8.79% over the month.
BioAtla Inc (BCAB) has around 65 employees, a market worth around $96.21M and $11.00M in sales. Profit margin for the company is -743.79%. Distance from 52-week low is 74.56% and -50.50% from its 52-week high. The company has generated returns on investments over the last 12 months (-356.22%).
The EPS is expected to grow by 40.93% this year
98.0 institutions hold shares in BioAtla Inc (BCAB), with institutional investors hold 56.35% of the company’s shares. The shares outstanding are 48.08M, and float is at 39.01M with Short Float at 12.48%. Institutions hold 50.29% of the Float.
The top institutional shareholder in the company is SOLEUS CAPITAL MANAGEMENT, L.P. with over 3.9 million shares valued at $5.34 million. The investor’s holdings represent 8.113 of the BCAB Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.89 million shares valued at $2.58 million to account for 3.9205 of the shares outstanding. The other top investors are MORGAN STANLEY which holds 1.85 million shares representing 3.8571 and valued at over $2.54 million, while MILLENNIUM MANAGEMENT LLC holds 3.4297 of the shares totaling 1.65 million with a market value of $2.26 million.
BioAtla Inc (BCAB) Insider Activity
The most recent transaction is an insider purchase by MCBRINN SYLVIA, the company’s Director. SEC filings show that MCBRINN SYLVIA bought 4,000 shares of the company’s common stock on Dec 26 ’23 at a price of $2.33 per share for a total of $9320.0. Following the purchase, the insider now owns 15125.0 shares.
BioAtla Inc disclosed in a document filed with the SEC on Dec 20 ’23 that SHORT JAY M PHD (Chief Executive Officer) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Dec 20 ’23 and was made at $2.14 per share for $0.11 million. Following the transaction, the insider now directly holds 1.44 million shares of the BCAB stock.
Still, SEC filings show that on Dec 19 ’23, STEINMAN LAWRENCE (Director) acquired 20,000 shares at an average price of $2.05 for $41048.0. The insider now directly holds 38,459 shares of BioAtla Inc (BCAB).
